Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
172 Leser
Artikel bewerten:
(0)

ADM Tronics Unlimited, Inc.: ADM Tronics Reports First Quarter of Fiscal Year 2019 Results

NORTHVALE, NJ / ACCESSWIRE / August 20, 2018 / ADM Tronics Unlimited, Inc. (OTCQB: ADMT), a technology-based developer and manufacturer of innovative technologies and products, today announced results for its first fiscal quarter ended June 30, 2018 of Fiscal Year 2019.

As previously announced, ADMT initiated its strategic plan to redefine its business growth strategy by redirecting more of its resources to the research, development, engineering and production of its own suite of proprietary medical technologies including Alvio ®, a respiratory training and therapeutic device for sufferers of asthma, COPD and other respiratory conditions; Aurex-3®, a therapeutic technology for the treatment and control of tinnitus; and, Sonotron®, a non-invasive treatment modality for pain. As these technologies go through various stages of development, revenues from engineering services and medical device manufacturing from clients is reduced while continuing to post a profit for the quarter.

"We are continuing our strategy to devote more of our engineering and development resources towards our own proprietary medical device technologies," stated Andre' DiMino, President of ADMT. "We believe increased efforts on our proprietary medical technologies is the best route for the future growth of the Company."

Revenues for the three months ended June 30, 2018 were $756,967 with a net income of $22,617 as compared to $1,146,355 and net income of $2,633 for June 30, 2017. Complete financial results are available in the Company's Quarterly Report on Form 10Q available at www.sec.gov.

Financial Highlights

Three Months Ended

Three Months Ended

June 30, 2018

June 30, 2017 (Restated)

Net Revenues

$756,967

$1,146,355

Cost of Sales

304,421

620,795

Gross Profit

452,546

525,560

Operating expenses:

Research and development

109,868

149,957

Selling, general and administrative

320,025

364,371

Depreciation and amortization

5,557

7,491

Total operating Expenses

435,450

521,819

Income from operations

17,096

3,741

Total other income

5,521

892

Income before provision for income taxes

22,617

4,633

Provision for income taxes:

Current

-

2,000

Net income

$22,617

$2,633

Net income per common share

$0.00

$0.00

Weighted average shares of common stock outstanding - diluted

67,588,504

67,588,504

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as 3-D solid prototyping, precision instrumentation and specialized software and peripherals, for the research, development and commercialization of diversified technologies. Additional information is available at the Company's website - admtronics.com

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact:

Andre' DiMino
201-767-6040
andre@admtronics.com

SOURCE: ADM Tronics Unlimited, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.